RVMD - Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker in a fireside chat at the TD Cowen 4 th Annual Oncology Innovation Summit.
Details of the company’s participation are as follows:
- TD Cowen 4 th Annual Oncology Innovation Summit
Conference Dates: May 30-31, 2023
Fireside Chat Time/Date: 12:30 p.m. Eastern on Wednesday, May 31, 2023
Location: Virtual conference; webcast available
To access the live webcast of the fireside chat, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations . Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RAS MULTI ) and RMC-6291(KRAS G12C ) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRAS G12D ) and RMC-0708 (KRAS Q61H ), both of which are currently in IND-enabling development, RMC-8839 (KRAS G13C ), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
Contact:For Investors & Media:Erin Graves650-779-0136egraves@revmed.com